Published in Managed Care Law Weekly, August 28th, 2005
The agreement accomplishes Abbott's objectives of helping Brazil expand patient access to Kaletra while preserving the company's intellectual property rights, which Abbott was not willing to negotiate.
The agreement does not specify a per-capsule price, and will not be at the low price quoted for local and generic manufacturers. The price of Kaletra will be dependent on the number of patients treated.
Abbott agreed to provide assistance to Brazil to enable local...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.